Discovering new treatments for Alzheimer's disease by repurposing approved medications

Current Topics in Medicinal Chemistry

Volumn 13, Issue 18, 2013, Pages 2306-2327

  Appleby, Brian S ^a,b   Cummings, Jeffrey L ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

Alzheimer's disease; Amyloid; Dementia; Medications; Neurodegenerative disease; Repurposing; Tau; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; AMPHOTERICIN B; APOMORPHINE; AZITHROMYCIN; BEXAROTENE; CARBAMAZEPINE; CLIOQUINOL; DAPSONE; DOXYCYCLINE; ERYTHROMYCIN; ETHOSUXIMIDE; ETIRACETAM; EXENDIN 4; GABAPENTIN; IBUPROFEN; IMATINIB; MEPACRINE; MINOCYCLINE; NICOTINE; NILOTINIB; PACLITAXEL; PHENYTOIN; PRAMIPEXOLE; PREGABALIN; RIFAMPICIN; TETRACYCLINE; THALIDOMIDE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN;

ABDOMINAL INFECTION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL INFECTION; BIPOLAR DISORDER; BLOOD BRAIN BARRIER; CHRONIC MYELOID LEUKEMIA; COGNITIVE DEFECT; CUTANEOUS T CELL LYMPHOMA; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DRUG EFFICACY; DRUG REPOSITIONING; DRUG TOLERABILITY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUNTINGTON CHOREA; LEUKEMIA; MULTIPLE SCLEROSIS; NEOPLASM; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRION DISEASE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SPINAL MUSCULAR ATROPHY; STREPTOCOCCUS INFECTION; TAUOPATHY; TRAUMATIC BRAIN INJURY; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

ALZHEIMER DISEASE; ANIMALS; DRUG DISCOVERY; DRUG REPOSITIONING; HUMANS;

EID: 84887924089     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113136660162     Document Type: Article

References (265)

1. Echávarri, C.; Burgmans, S.; Caballero, M. C.; García-Bragado, F.; Verhey, F. R. J.; Uylings, H. B. M. Co-occurrence of different pathologies in dementia: implications for dementia diagnosis. Journal of Alzheimer's Disease, 2012, 30, 909-917.
2. Morales, R.; Green, K. M.; Soto C. Cross Currents in Protein Misfolding Disorders: Interactions and Therapy. CNS Neurol. Disord. Drug Targets, 2009, 8(5), 363-371.
3. Alzheimer's Association. 2012 Alzheimer"s disease facts and figures. Alzheimers Dement, 2012, 8(2), 131-168.
4. Ory, M. G.; Hoffman, R. R.; Yee, J. L.; Tennstedt, S.; Schulz, R. Prevalence and impact of caregiving: a detailed comparison between dementia and nondementia caregivers. The Gerontologist, 1999, 39, 177-185.
5. Norton, M. C.; Smith, K. R.; Østbye, T.; Tschanz, J. T.; Corcoran, C.; Schwartz, S.; Piercy, K. W.; Rabins, P. V.; Steffens, D. C.; Skoog, I.; Breitner, J. C. S.; Welsh-Bohmer, K. A.; Cache County Investigators. Greater risk of dementia when spouse has dementia? The Cache County study. Journal of the American Geriatrics Society, 2010, 58, 895-900.
6. Villemagne, V. L.; Burnham, S.; Bourgeat, P.; Brown, B.; Ellis, K. A.; Salvado, O.; Szoeke, C.; Macaulay, S. L.; Martins, R.; Maruff, P.; Ames, D.; Rowe, C. C.; Masters, C. L.; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurology, 2013, 12, 357-367.
7. McKhann, G. M.; Knopman, D. S.; Chertkow, H.; Hyman, B. T.; Jack, C. R.; Kawas, C. H.; Klunk, W. E.; Koroshetz, W. J.; Manly, J. J.; Mayeux, R.; Mohs, R. C.; Morris, J. C.; Rossor, M. N.; Scheltens, P.; Carrillo, M. C.; Thies, B.; Weintraub, S.; Phelps, C. H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011, 7(3), 263-269.
8. Dubois, B.; Feldman, H. H.; Jacova, C.; DeKosky, S. T.; Barberger-Gateau, P.; Cummings, J.; Delacourte, A. E.; Galasko, D.; Gauthier, S.; Jicha, G.; Meguro, K.; O'Brien, J.; Pasquier, F.; Robert, P.; Rossor, M.; Salloway, S.; Stern, Y.; Visser, P. J.; Scheltens, P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurology, 2007, 6, 734-746.
9. Alzheimer, A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrife Psychiatrie, 1907, 64, 146-148.
10. Appleby, B. S.; Nacopoulos, D.; Milano, N.; Zhong, K.; Cummings, J. L. A Review: Treatment of Alzheimer's Disease Discovered in Repurposed Agents. Dement. Geriatr. Cogn. Disord, 2013, 35, 1-22.
11. Brunden, K. R.; Yao, Y.; Potuzak, J. S.; Ferrer, N. I.; Ballatore, C.; James, M. J.; Hogan, A. M. L.; Trojanowski, J. Q.; Smith, A. B.; Lee, V. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. Pharmacol. Res, 2011, 63, 341-351.
12. Tanaka, T.; Zhong, J.; Iqbal, K.; Trenkner, E.; Grundke-Iqbal, I. The regulation of phosphorylation of tau in SY5Y neuroblastoma cells: the role of protein phosphatases. FEBS Letters, 1998, 426, 248-254.
13. Zhang, B.; Maiti, A.; Shively, S.; Lakhani, F.; McDonald-Jones, G.; Bruce, J.; Lee, E. B.; Xie, S. X.; Joyce, S.; Li, C.; Toleikis, P. M.; Lee, V.; Trojanowski, J. Q. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 227-231.
14. Canu, N.; Dus, L.; Barbato, C.; Ciotti, M. T.; Brancolini, C.; Rinaldi, A. M.; Novak, M.; Cattaneo, A.; Bradbury, A.; Calissano, P. Tau cleavage and dephosphorylation in cerebellar granule neurons undergoing apoptosis. J. Neurosci, 1998, 18, 7061-7074.
15. Michaelis, M. L.; Ranciat, N.; Chen, Y.; Bechtel, M.; Ragan, R.; Hepperle, M.; Liu, Y.; Georg, G. Protection Against β-Amyloid Toxicity in Primary Neurons by Paclitaxel (Taxol). Journal of Neurochemistry, 2002, 70, 1623-1627.
16. Shemesh, O. A.; Spira, M. E. Rescue of neurons from undergoing hallmark tau-induced Alzheimer's disease cell pathologies by the antimitotic drug paclitaxel. Neurobiology of Disease, 2011, 43, 163-175.
17. Cancino, G. I.; Toledo, E. M.; Leal, N. R.; Hernandez, D. E.; Yévenes, L. F.; Inestrosa, N. C.; Alvarez, A. R. (2008) STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's beta-amyloid deposits. Brain, 2008, 131, 2425-2442.
18. Netzer, W. J.; Dou, F.; Cai, D.; Veach, D.; Jean, S.; Li, Y.; Bornmann, W. G.; Clarkson, B.; Xu, H.; Greengard, P. Gleevec inhibits beta-amyloid production but not Notch cleavage. Proceedings of the National Academy of Sciences, 2003, 100, 12444-12449.
19. Fraering, P. C.; Ye, W.; LaVoie, M. J.; Ostaszewski, B. L.; Selkoe, D. J.; Wolfe, M. S. gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. Journal of Biological Chemistry, 2005, 280, 41987-41996.
20. He, G.; Luo, W.; Li, P.; Remmers, C.; Netzer, W. J.; Hendrick, J.; Bettayeb, K.; Flajolet, M.; Gorelick, F.; Wennogle, L. P.; Greengard, P. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature, 2010, 467, 95-98.
21. Hussain, I.; Fabrègue, J.; Anderes, L.; Ousson, S.; Borlat, F.; Eligert, V.; Berger, S.; Dimitrov, M.; Alattia, J. R.; Fraering, P. C.; Beher, D. The role of β-secretase activating protein (GSAP) and imatinib in the regulation of β-secretase activity and amyloid-α generation. Journal of Biological Chemistry, 2013, 288, 2521-2531.
22. Sutcliffe, J. G.; Hedlund, P. B.; Thomas, E. A.; Bloom, F. E.; Hilbush, B. S. Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: implications for Alzheimer's disease. Journal of Neuroscience Research, 2011, 89, 808-814.
23. Weintraub, M. K.; Bisson, C. M.; Nouri, J. N.; Vinson, B. T.; Kranjac, D.; Eimerbrink, M. J.; Boehm, G. W.; Chumley, M. J. Imatinib methanesulfonate reduces hippocampal amyloid-beta and restores cognitive function following repeated endotoxin exposure. Brain Behav. Immun, 2013, [In Press].
24. Ryu, J. K.; McLarnon, J. G. Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain., Neurobiology of Disease, 2008, 29, 254-266.
25. Alkam, T.; Nitta, A.; Mizoguchi, H.; Saito, K.; Seshima, M.; Itoh, A.; Yamada, K.; Nabeshima, T. Restraining tumor necrosis factoralpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice. Behav. Brain Res, 2008, 189, 100-106.
26. Elçiolu, H.; Kabasakal, L.; Alan, S.; Salva, E.; Tufan, F.; Karan, M. Thalidomide attenuates learning and memory deficits induced by intracerebroventricular administration of streptozotocin in rats. Biotech. Histochem, 2013, 88, 145-152.
27. Gabbita, S. P.; Srivastava, M. K.; Eslami, P.; Johnson, M. F.; Kobritz, N. K.; Tweedie, D.; Greig, N. H.; Zemlan, F. P.; Sharma, S. P.; Harris-White, M. E. Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. J. Neuroinflammation, 2012, 9, 99.
28. He, P.; Cheng, X.; Staufenbiel, M.; Li, R.; Shen, Y. Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease. PloS One, 2013, 8, e55091.
29. Russo, I.; Caracciolo, L.; Tweedie, D.; Choi, S. H.; Greig, N. H.; Barlati, S.; Bosetti, F. 3, 6'-Dithiothalidomide, a new TNF-α synthesis inhibitor, attenuates the effect of Aβ1-42 intracerebroventricular injection on hippocampal neurogenesis and memory deficit. Journal of Neurochemistry, 2012, 122, 1181-1192.
30. Tweedie, D.; Ferguson, R. A.; Fishman, K.; Frankola, K. A.; Van Praag, H.; Holloway, H. W.; Luo, W.; Li, Y.; Caracciolo, L.; Russo, I.; Barlati, S.; Ray, B.; Lahiri, D. K.; Bosetti, F.; Greig, N. H.; Rosi, S. Tumor necrosis factor-α synthesis inhibitor 3, 6"-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroin flammation and Alzheimer's disease. J. Neuroinflammation, 2012, 9, 106.
31. Tweedie, D.; Luo, W.; Short, R. G.; Brossi, A.; Holloway, H. W.; Li, Y.; Yu, Q. S.; Greig, N. H. A cellular model of inflammation for identifying TNF-alpha synthesis inhibitors. J. Neurosci. Methods, 2009, 183, 182-187.
32. Cramer, P. E.; Cirrito, J. R.; Wesson, D. W.; Lee, C. Y. D.; Karlo, J. C.; Zinn, A. E.; Casali, B. T.; Restivo, J. L.; Goebel, W. D.; James, M. J.; Brunden, K. R.; Wilson, D. A.; Landreth, G. E. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science, 2012, 335, 1503-1506.
33. Yamanaka, M.; Ishikawa, T.; Griep, A.; Axt, D.; Kummer, M. P.; Heneka, M. T. PPAR_/RXRβ-induced and CD36-mediated microglial amyloid-α phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. The Journal of Neuroscience, 2012, 32, 17321-17331.
34. Fitz, N. F.; Cronican, A. A.; Lefterov, I.; Koldamova, R. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. " Science, 2013, 340, 924-c.
35. Price, A. R.; Xu, G.; Siemienski, Z. B.; Smithson, L. A.; Borchelt, D. R.; Golde, T. E.; Felsenstein, K. M. Comment on "ApoEdirected therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. " Science, 2013, 340, 924-d.
36. Tesseur, I.; Lo, A. C.; Roberfroid, A.; Dietvorst, S.; Van Broeck, B.; Borgers, M.; Gijsen, H.; Moechars, D.; Mercken, M.; Kemp, J.; D'Hooge, R.; De Strooper, B. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. " Science, 2013, 340, 924-e.
37. Veeraraghavalu, K.; Zhang, C.; Miller, S.; Hefendehl, J. K.; Rajapaksha, T. W.; Ulrich, J.; Jucker, M.; Holtzman, D. M.; Tanzi, R. E.; Vassar, R.; Sisodia, S. S. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. " Science, 2013, 340, 924-f.
38. Landreth, G. E.; Cramer, P. E.; Lakner, M. M.; Cirrito, J. R.; Wesson, D. W.; Brunden, K. R.; Wilson, D. A. Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. " Science, 2013, 340, 924-g.
39. Hebron, M. L.; Lonskaya, I.; Moussa, C. E. H. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of β-synuclein in Parkinson's disease models. Hum. Mol. Genet, 2013, [In Press].
40. Tucker, S.; Ahl, M.; Cho, H. H.; Bandyopadhyay, S.; Cuny, G. D.; Bush, A. I.; Goldstein, L. E.; Westaway, D.; Huang, X.; Rogers, J. T. RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine. Current Alzheimer Research, 2006, 3, 221-227.
41. Grossi, C.; Francese, S.; Casini, A.; Rosi, M. C.; Luccarini, I.; Fiorentini, A.; Gabbiani, C.; Messori, L.; Moneti, G.; Casamenti, F. Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. Journal of Alzheimer's Disease, 2009, 17, 423-440.
42. Sampson, E.; Jenagaratnam, L.; McShane, R. Metal protein attenuating compounds for the treatment of Alzheimer's disease. Cochrane Database Syst. Rev, 2008, CD005380.
43. Ritchie, C. W.; Bush, A. I.; Mackinnon, A.; Macfarlane, S.; Mastwyk, M.; MacGregor, L.; Kiers, L.; Cherny, R.; Li, Q. X.; Tammer, A.; Carrington, D.; Mavros, C.; Volitakis, I.; Xilinas, M.; Ames, D.; Davis, S.; Beyreuther, K.; Tanzi, R. E.; Masters, C. L. Metalprotein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol, 2003, 60, 1685-1691.
44. Faux, N. G.; Ritchie, C. W.; Gunn, A.; Rembach, A.; Tsatsanis, A.; Bedo, J.; Harrison, J.; Lannfelt, L.; Blennow, K.; Zetterberg, H.; Ingelsson, M.; Masters, C. L.; Tanzi, R. E.; Cummings, J. L.; Herd, C. M.; Bush, A. I. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. Journal of Alzheimer's Disease, 2010, 20, 509-516.
45. Cameron, A. R.; Wallace, K.; Logie, L.; Prescott, A. R.; Unterman, T. G.; Harthill, J.; Rena, G. The anti-neurodegenerative agent clioquinol regulates the transcription factor FOXO1a. The Biochemical Journal, 2012, 443, 57-64.
46. Lei, P.; Ayton, S.; Finkelstein, D. I.; Spoerri, L.; Ciccotosto, G. D.; Wright, D. K.; Wong, B. X. W.; Adlard, P. A.; Cherny, R. A.; Lam, L. Q.; Roberts, B. R.; Volitakis, I.; Egan, G. F.; McLean, C. A.; Cappai, R.; Duce, J. A.; Bush, A. I. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med, 2012, 18, 291-295.
47. Zhang, Y. H.; Raymick, J.; Sarkar, S.; Lahiri, D. K.; Ray, B.; Holtzman, D.; Dumas, M.; Schmued, L. C. Efficacy and Toxicity of Clioquinol Treatment and A-beta42 Inoculation in the APP/PSI Mouse Model of Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 494-506.
48. Diomede, L.; Cassata, G.; Fiordaliso, F.; Salio, M.; Ami, D.; Natalello, A.; Doglia, S. M.; de Luigi, A.; Salmona, M. Tetracycline and its analogues protect Caenorhabditis elegans from amyloidinduced toxicity by targeting oligomers. Neurobiology of Disease, 2010, 40, 424-431.
49. Forloni, G.; Colombo, L.; Girola, L.; Tagliavini, F.; Salmona, M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Letters, 2001, 487, 404-407.
50. Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M. Antiamyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro. Biochim. Biophys. Acta, 2004, 1690, 193-202.
51. Naldi, M.; Fiori, J.; Pistolozzi, M.; Drake, A. F.; Bertucci, C.; Wu, R.; Mlynarczyk, K.; Filipek, S.; De Simone, A.; Andrisano, V. Amyloid β-peptide 25-35 self-assembly and its inhibition: a model undecapeptide system to gain atomistic and secondary structure details of the Alzheimer's disease process and treatment. ACS Chem. Neurosci, 2012, 3, 952-962.
52. Costa, R.; Speretta, E.; Crowther, D. C.; Cardoso, I. Testing the therapeutic potential of doxycycline in a Drosophila melanogaster model of Alzheimer disease. Journal of Biological Chemistry, 2011, 286, 41647-41655.
53. Forloni, G.; Salmona, M.; Marcon, G.; Tagliavini, F. Tetracyclines and prion infectivity. Infectious Disorders Drug Targets, 2009, 9, 23-30.
54. Loeb, M. B.; Molloy, D. W.; Smieja, M.; Standish, T.; Goldsmith, C. H.; Mahony, J.; Smith, S.; Borrie, M.; Decoteau, E.; Davidson, W.; McDougall, A.; Gnarpe, J.; O'Donnell, M.; Chernesky, M. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. Journal of the American Geriatrics Society, 2004, 52, 381-387.
55. Molloy, D. W.; Standish, T. I.; Zhou, Q.; Guyatt, G.; The DARAD Study Group. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial. Int. J. Geriatr. Psychiatry, 2012, 28(5), 463-470.
56. Ravina, B. M.; Fagan, S. C.; Hart, R. G.; Hovinga, C. A.; Murphy, D. D.; Dawson, T. M.; Marler, J. R. Neuroprotective agents for clinical trials in Parkinson's disease A systematic assessment. Neurology, 2003, 60, 1234-1240.
57. Choi, Y.; Kim, H. S.; Shin, K. Y.; Kim, E. M.; Kim, M.; Kim, H. S.; Park, C. H.; Jeong, Y. H.; Yoo, J.; Lee, J. P.; Chang, K. A.; Kim, S.; Suh, Y. H. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology, 2007, 32, 2393-2404.
58. Garwood, C. J.; Cooper, J. D.; Hanger, D. P.; Noble, W. Antiinflammatory impact of minocycline in a mouse model of tauopathy. Front. Psychiatry, 2010, 1, 136.
59. Hashimoto, K. Can minocycline prevent the onset of Alzheimer's disease? Annals of Neurology, 2011, 69, 739; author reply 739-40.
60. Cuello, A. C.; Ferretti, M. T.; Leon, W. C.; Iulita, M. F.; Melis, T.; Ducatenzeiler, A.; Bruno, M. A.; Canneva, F. Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neuro-Degenerative Diseases, 2010, 7, 96-98.
61. Noble, W.; Garwood, C.; Stephenson, J.; Kinsey, A. M.; Hanger, D. P.; Anderton, B. H. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. The FASEB Journal, 2009, 23, 739-750.
62. Parachikova, A.; Vasilevko, V.; Cribbs, D. H.; LaFerla, F. M.; Green, K. N. Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. Journal of Alzheimer's Disease, 2010, 21, 527-542.
63. Ryu, J. K.; Franciosi, S.; Sattayaprasert, P.; Kim, S. U.; McLarnon, J. G. Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus. Glia, 2004, 48, 85-90.
64. Seabrook, T. J.; Jiang, L.; Maier, M.; Lemere, C. A. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia, 2006, 53, 776-782.
65. Wang, Q.; Rowan, M. J.; Anwyl, R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. The Journal of Neuroscience, 2004, 24, 6049-6056.
66. Garwood, C. J.; Pooler, A. M.; Atherton, J.; Hanger, D. P.; Noble, W. Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis, 2011, 2, e167.
67. Biscaro, B.; Lindvall, O.; Tesco, G.; Ekdahl, C. T.; Nitsch, R. M. Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer's disease. Neuro-Degenerative Diseases, 2012, 9, 187-198.
68. Cai, Z.; Zhao, Y.; Yao, S.; Bin Zhao, B. Increases in β-amyloid protein in the hippocampus caused by diabetic metabolic disorder are blocked by minocycline through inhibition of NF-αB pathway activation. Pharmacol. Rep, 2011, 63, 381-391.
69. Ferretti, M. T.; Allard, S.; Partridge, V.; Ducatenzeiler, A.; Cuello, A. C. Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's diseaselike amyloid pathology. J. Neuroinflammation, 2012, 9, 62.
70. Payton, S.; Cahill, C. M.; Randall, J. D.; Gullans, S. R.; Rogers, J. T. Drug discovery targeted to the Alzheimer's APP mRNA 5-'untranslated region: the action of paroxetine and dimercaptopropano. J. Mol. Neurosci, 2003, 20, 267-275.
71. Morse, L. J.; Payton, S. M.; Cuny, G. D.; Rogers, J. T. FDApreapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. J. Mol. Neurosci, 2004, 24, 129-136.
72. Tomiyama, T.; Shoji, A.; Kataoka, K.; Suwa, Y.; Asano, S.; Kaneko, H.; Endo, N. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. Journal of Biological Chemistry, 1996, 271, 6839-6844.
73. Abuznait, A. H.; Cain, C.; Ingram, D.; Burk, D.; Kaddoumi, A. Upregulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease. J. Pharm. Pharmacol, 2011, 63, 1111-1118.
74. Qosa, H.; Abuznait, A. H.; Hill, R. A.; Kaddoumi, A. Enhanced brain amyloid-α clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. Journal of Alzheimer's Disease, 2012, 31, 151-165.
75. Hartsel, S. C.; Weiland, T. R. Amphotericin B binds to amyloid fibrils and delays their formation: a therapeutic mechanism? Biochemistry, 2003, 42, 6228-6233.
76. Smith, N. W.; Annunziata, O.; Dzyuba, S. V. Amphotericin B interactions with soluble oligomers of amyloid Abeta1-42 peptide. Bioorg. Med. Chem, 2009, 17, 2366-2370.
77. Haik, S.; Brandel, J. P.; Salomon, D.; Sazdovitch, von, Delasnerie-Laupretre, N.; Laplanche, J. L.; Faucheux, B. A.; Soubrie, C.; Boher, E.; Belorgey, C.; Hauw, J. J.; Alperovitch, A. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology, 2004, 63, 2413-2415.
78. Collinge, J.; Gorham, M.; Hudson, F.; Kennedy, A.; Keogh, G.; Pal, S.; Rossor, M.; Rudge, P.; Siddique, D.; Spyer, M.; Thomas, D.; Walker, S.; Webb, T.; Wroe, S.; Darbyshire, J. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurology, 2009, 8, 334-344.
79. Korth, C.; May, B. C.; Cohen, F. E.; Prusiner, S. B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 9836-9841.
80. Taniguchi, S.; Suzuki, N.; Masuda, M.; Hisanaga, S. I.; Iwatsubo, T.; Goedert, M.; Hasegawa, M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. The Journal of Biological Chemistry, 2005, 280, 7614-7623.
81. Csuk, R.; Barthel, A.; Raschke, C.; Kluge, R.; Ströhl, D.; Trieschmann, L.; Böhm, G. Synthesis of monomeric and dimeric acridine compounds as potential therapeutics in Alzheimer and prion diseases. Arch. Pharm, 2009, 342, 699-709.
82. McGeer, P. L.; Harada, N.; Kimura, H.; McGeer, E. G.; Schulzer, M. Prevalence of Dementia amongst Elderly Japanese with Leprosy: Apparent Effect of Chronic Drug Therapy. Dement. Geriatr. Cogn. Disord, 1992, 3, 146-149.
83. Goto, M.; Kimura, T.; Hagio, S.; Ueda, K.; Kitajima, S.; Tokunaga, H.; Sato, E. Neuropathological analysis of dementia in a Japanese leprosarium. Dementia, 1995, 6, 157-161.
84. Namba, Y.; Kawatsu, K.; Izumi, S.; Ueki, A.; Ikeda, K. Neurofibrillary tangles and senile plaques in brain of elderly leprosy patients. Lancet, 1992, 340, 978.
85. Kimura, T.; Goto, M. Existence of senile plaques in the brains of elderly leprosy patients. Lancet, 1993, 342, 1364.
86. Chui, D. H.; Tabira, T.; Izumi, S.; Koya, G.; Ogata, J. Decreased beta-amyloid and increased abnormal Tau deposition in the brain of aged patients with leprosy. AJPA, 1994, 145, 771-775.
87. Endoh, M.; Kunishita, T.; Tabira, T. No effect of anti-leprosy drugs in the prevention of Alzheimer's disease and beta-amyloid neurotoxicity. Journal of the Neurological Sciences, 1999, 165, 28-30.
88. Wozniak, M. A.; Frost, A. L.; Preston, C. M.; Itzhaki, R. F. Antivirals Reduce the Formation of Key Alzheimer's Disease Molecules in Cell Cultures Acutely Infected with Herpes Simplex Virus Type 1. PloS One, 2011, 6, e25152.
89. Wozniak, M. A.; Itzhaki, R. F. Intravenous immunoglobulin reduces amyloid and abnormal tau formation caused by herpes simplex virus type 1. J. Neuroimmunol, 2013, 257, 7-12.
90. Smith, A. M.; Gibbons, H. M.; Dragunow, M. Valproic acid enhances microglial phagocytosis of amyloid-beta(1-42). Neuroscience, 2010, 169, 505-515.
91. Nalivaeva, N. N.; Belyaev, N. D.; Lewis, D. I.; Pickles, A. R.; Makova, N. Z.; Bagrova, D. I.; Dubrovskaya, N. M.; Plesneva, S. A.; Zhuravin, I. A.; Turner, A. J. Effect of sodium valproate administration on brain neprilysin expression and memory in rats. J. Mol. Neurosci, 2012, 46, 569-577.
92. Wang, Z.; Yang, D.; Zhang, X.; Li, T.; Li, J.; Tang, Y.; Le, W. Hypoxia-induced down-regulation of neprilysin by histone modification in mouse primary cortical and hippocampal neurons. PloS One, 2011, 6, e19229.
93. Hu, J. P.; Xie, J. W.; Wang, C. Y.; Wang, T.; Wang, X.; Wang, S. L.; Teng, W. P.; Wang, Z. Y. Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways. Brain Res. Bull, 2011, 85, 194-200.
94. Long, Z.; Zheng, M.; Zhao, L.; Xie, P.; Song, C.; Chu, Y.; Song, W.; He, G. Valproic Acid Attenuates Neuronal Loss in the Brain of APP/PS1 Double Transgenic Alzheimer's Disease Mice Model. Current Alzheimer Research, 2013, 10, 261-269.
95. Tariot, P. N.; Schneider, L. S.; Cummings, J.; Thomas, R. G.; Raman, R.; Jakimovich, L. J.; Loy, R.; Bartocci, B.; Fleisher, A.; Ismail, M. S.; Porsteinsson, A.; Weiner, M.; Jack, C. R.; Thal, L.; Aisen, P. S.; Alzheimer's Disease Cooperative Study Group. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch. Gen. Psychiatry, 2011, 68, 853-861.
96. Bakker, A.; Krauss, G. L.; Albert, M. S.; Speck, C. L.; Jones, L. R.; Stark, C. E.; Yassa, M. A.; Bassett, S. S.; Shelton, A. L.; Gallagher, M. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron, 2012, 74, 467-474.
97. Sanchez, P. E.; Zhu, L.; Verret, L.; Vossel, K. A.; Orr, A. G.; Cirrito, J. R.; Devidze, N.; Ho, K.; Yu, G. Q.; Palop, J. J.; Mucke, L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proceedings of the National Academy of Sciences, 2012, 109, E2895-2903.
98. Devi, L.; Ohno, M. Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice. Neurobiol. Learn. Mem, 2013, 102, 7-11.
99. Li, L.; Zhang, S.; Zhang, X.; Li, T.; Tang, Y.; Liu, H.; Yang, W.; Le, W. Autophagy Enhancer Carbamazepine Alleviates Memory Deficits and Cerebral Amyloid-α Pathology in a Mouse Model of Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 433-441.
100. Lashuel, H. A.; Hartley, D. M.; Balakhaneh, D.; Aggarwal, A.; Teichberg, S.; Callaway, D. J. E. New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. The Journal of Biological Chemistry, 2002, 277, 42881-42890.
101. Himeno, E.; Ohyagi, Y.; Ma, L.; Nakamura, N.; Miyoshi, K.; Sakae, N.; Motomura, K.; Soejima, N.; Yamasaki, R.; Hashimoto, T.; Tabira, T.; M LaFerla, F.; Kira, J. I. Apomorphine treatment in Alzheimer mice promoting amyloid-α degradation. Annals of Neurology, 2011, 69, 248-256.
102. Uberti, D.; Bianchi, I.; Olivari, L.; Ferrari-Toninelli, G.; Canonico, P.; Memo, M. Pramipexole prevents neurotoxicity induced by oligomers of beta-amyloid. Eur. J. Pharmacol, 2007, 569, 194-196.
103. Ofengeim, D.; Shi, P.; Miao, B.; Fan, J.; Xia, X.; Fan, Y.; Lipinski, M. M.; Hashimoto, T.; Polydoro, M.; Yuan, J.; Wong, S. T. C.; Degterev, A. Identification of small molecule inhibitors of neurite loss induced by Aβ peptide using high content screening. Journal of Biological Chemistry, 2012, 287, 8714-8723.
104. Hillmann, A.; Hahn, S.; Schilling, S.; Hoffmann, T.; Demuth, H. U.; Bulic, B.; Schneider-Axmann, T.; Bayer, T. A.; Weggen, S.; Wirths, O. No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 833. e39-50.
105. Wilkinson, B. L.; Cramer, P. E.; Varvel, N. H.; Reed-Geaghan, E.; Jiang, Q.; Szabo, A.; Herrup, K.; Lamb, B. T.; Landreth, G. E. Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 197. e21-32.
106. Sekiyama, K.; Fujita, M.; Sekigawa, A.; Takamatsu, Y.; Waragai, M.; Takenouchi, T.; Sugama, S.; Hashimoto, M. Ibuprofen ameliorates protein aggregation and astrocytic gliosis, but not cognitive dysfunction, in a transgenic mouse expressing dementia with Lewy bodies-linked P123H β-synuclein. Neuroscience Letters, 2012, 515, 97-101.
107. Jaturapatporn, D.; Isaac, M. G. E. K. N.; McCleery, J.; Tabet, N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst. Rev, 2012, 2, CD006378.
108. Liu, Y. Y.; Sparatore, A.; Del Soldato, P.; Bian, J. S. H2S releasing aspirin protects amyloid beta induced cell toxicity in BV-2 microglial cells. Neuroscience, 2011, 193, 80-88.
109. Dhull, D. K.; Jindal, A.; Dhull, R. K.; Aggarwal, S.; Bhateja, D.; Padi, S. S. V. Neuroprotective effect of cyclooxygenase inhibitors in ICV-STZ induced sporadic Alzheimer's disease in rats. J. Mol. Neurosci, 2012, 46, 223-235.
110. Leoutsakos, J. M. S.; Muthen, B. O.; Breitner, J. C. S.; Lyketsos, C. G.; ADAPT Research Team. Effects of non-steroidal antiinflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. Int. J. Geriatr. Psychiatry, 2012, 27, 364-374.
111. Bernardi, A.; Frozza, R. L.; Meneghetti, A.; Hoppe, J. B.; Battastini, A. M. O.; Pohlmann, A. R.; Guterres, S. S.; Salbego, C. G. Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer's disease models. Int. J. Nanomedicine, 2012, 7, 4927-4942.
112. Magga, J.; Puli, L.; Pihlaja, R.; Kanninen, K.; Neulamaa, S.; Malm, T.; Härtig, W.; Grosche, J.; Goldsteins, G.; Tanila, H.; Koistinaho, J.; Koistinaho, M. Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J. Neuroinflammation, 2010, 7, 90.
113. Widiapradja, A.; Vegh, V.; Lok, K. Z.; Manzanero, S.; Thundyil, J.; Gelderblom, M.; Cheng, Y. L.; Pavlovski, D.; Tang, S. C.; Jo, D. G.; Magnus, T.; Chan, S. L.; Sobey, C. G.; Reutens, D.; Basta, M.; Mattson, M. P.; Arumugam, T. V. Intravenous immunoglobulin protects neurons against amyloid beta-peptide toxicity and ischemic stroke by attenuating multiple cell death pathways. Journal of Neurochemistry, 2012, 122(2), 321-332.
114. Dodel, R.; Rominger, A.; Bartenstein, P.; Barkhof, F.; Blennow, K.; Förster, S.; Winter, Y.; Bach, J. P.; Popp, J.; Alferink, J.; Wiltfang, J.; Buerger, K.; Otto, M.; Antuono, P.; Jacoby, M.; Richter, R.; Stevens, J.; Melamed, I.; Goldstein, J.; Haag, S.; Wietek, S.; Farlow, M.; Jessen, F. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurology, 2013, 12, 233-243.
115. Zemer, D.; Livneh, A.; Langevitz, P. Reversal of the nephrotic syndrome by colchicine in amyloidosis of familial Mediterranean fever. Ann. Intern. Med, 1992, 116, 426.
116. Aisen, P. S.; Marin, D. B.; Brickman, A. M.; Santoro, J.; Fusco, M. Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease. Alzheimer Disease and Associated Disorders, 2001, 15, 96-101.
117. Refolo, L. M.; Sambamurti, K.; Efthimiopoulos, S.; Pappolla, M. A.; Robakis, N. K. Evidence that secretase cleavage of cell surface Alzheimer amyloid precursor occurs after normal endocytic internalization. Journal of Neuroscience Research, 1995, 40, 694-706.
118. Lauterbach, E. C.; Victoroff, J.; Coburn, K. L.; Shillcutt, S. D.; Doonan, S. M.; Mendez, M. F. Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J. Neuropsychiatry Clin. Neurosci, 2010, 22, 8-18.
119. Camins, A.; Verdaguer, E.; Junyent, F.; Yeste-Velasco, M.; Pelegrí, C.; Vilaplana, J.; Pallás, M. Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium. CNS Neurosci. Ther, 2009, 15, 333-344.
120. Hampel, H.; Ewers, M.; Bürger, K.; Annas, P.; Mörtberg, A.; Bogstedt, A.; Frölich, L.; Schröder, J.; Schönknecht, P.; Riepe, M. W.; Kraft, I.; Gasser, T.; Leyhe, T.; Möller, H. J.; Kurz, A.; Basun, H. Lithium Trial in Alzheimer's Disease. The Journal of Clinical Psychiatry, 2009, 70, 922-931.
121. Forlenza, O. V.; Diniz, B. S.; Radanovic, M.; Santos, F. S.; Talib, L. L.; Gattaz, W. F. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. The British Journal of Psychiatry, 2011, 198, 351-356.
122. Nunes, M. A.; Viel, T. A.; Buck, H. S. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Current Alzheimer Research, 2013, 10, 104-107.
123. Hellweg, R.; Ziegenhorn, A.; Heuser, I.; Deuschle, M. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry, 2008, 41, 66-71.
124. Chadwick, W.; Mitchell, N.; Caroll, J.; Zhou, Y.; Park, S. S.; Wang, L.; Becker, K. G.; Zhang, Y.; Lehrmann, E.; Wood, W. H.; Martin, B.; Maudsley, S. Amitriptyline-mediated cognitive enhancement in aged 3-Tg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity. PloS One, 2011, 6, e21660.
125. Marlatt, M. W.; Potter, M. C.; Bayer, T. A.; Van Praag, H.; Lucassen, P. J. Prolonged Running, not Fluoxetine Treatment, Increases Neurogenesis, but does not Alter Neuropathology, in the 3xTg Mouse Model of Alzheimer's Disease. Curr Top Behav Neurosci, 2013, 15, 313-340.
126. Appleby, B. S.; Roy, P.; Valenti, A.; Lee, H. B. Diagnosis and treatment of depression in Alzheimer's disease: impact on mood and cognition. Panminerva medica, 2007, 49, 139-149.
127. Cirrito, J. R.; Disabato, B. M.; Restivo, J. L.; Verges, D. K.; Goebel, W. D.; Sathyan, A.; Hayreh, D.; D'Angelo, G.; Benzinger, T.; Yoon, H.; Kim, J.; Morris, J. C.; Mintun, M. A.; Sheline, Y. I. Serotonin signaling is associated with lower amyloid-α levels and plaques in transgenic mice and humans. Proceedings of the National Academy of Sciences, 2011, 108, 14968-14973.
128. Youdim, M. B. H. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Current Alzheimer Research, 2006, 3, 541-550.
129. Jenner, P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology, 2004, 63, S13-22.
130. Youdim, M. B. H.; Bar Am, O.; Yogev-Falach, M.; Weinreb, O.; Maruyama, W.; Naoi, M.; Amit, T. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. Journal of Neuroscience Research, 2005, 79, 172-179.
131. Matveychuk, D.; Nunes, E.; Ullah, N.; Velázquez-Martinez, C. A.; Mackenzie, E. M.; Baker, G. B. Comparison of phenelzine and geometric isomers of its active metabolite, β-phenylethylidenehydrazine, on rat brain levels of amino acids, bio genic amine neurotransmitters and methylamine. Journal of Neural Transmission, 2013, 120(6), 987-996.
132. Luedtke, R. R.; Perez, E.; Yang, S. H.; Liu, R.; Vangveravong, S.; Tu, Z.; Mach, R. H.; Simpkins, J. W. Neuroprotective effects of high affinity 1 receptor selective compounds. Brain Research, 2012, 1441, 17-26.
133. Kodama, M.; Fujioka, T. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biological Psychiatry, 2004, 56, 570-580.
134. Zhu, S.; He, J.; Zhang, R.; Kong, L.; Tempier, A.; Kong, J.; Li, X. M. Therapeutic Effects of Quetiapine on Memory Deficit and Brain β-Amyloid Plaque Pathology in a Transgenic Mouse Model of Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 270-278.
135. Kennedy, J.; Deberdt, W.; Siegal, A.; Micca, J.; Degenhardt, E.; Ahl, J.; Meyers, A.; Kaiser, C.; Baker, R. W. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. Int. J. Geriatr. Psychiatry, 2005, 20, 1020-1027.
136. Vigen, C. L. P.; Mack, W. J.; Keefe, R. S. E.; Sano, M.; Sultzer, D. L.; Stroup, T. S.; Dagerman, K. S.; Hsiao, J. K.; Lebowitz, B. D.; Lyketsos, C. G.; Tariot, P. N.; Zheng, L.; Schneider, L. S. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. The American Journal of Psychiatry, 2011, 168, 831-839.
137. Butterfield, D. A.; Barone, E.; Di Domenico, F.; Cenini, G.; Sultana, R.; Murphy, M. P;, Mancuso, C.; Head, E. Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to upregulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. Int. J. Neuropsychopharmacol, 2012, 15, 981-987.
138. Kurata, T.; Miyazaki, K.; Morimoto, N.; Kawai, H.; Ohta, Y.; Ikeda, Y.; Abe, K. Atorvastatin and pitavastatin reduce oxidative stress and improve IR/LDL-R signals in Alzheimer's disease. Neurol. Res, 2013, 35, 193-205.
139. Kurata, T.; Miyazaki, K.; Kozuki, M.; Morimoto, N.; Ohta, Y.; Ikeda, Y; Abe, K. Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease. Neurol. Res, 2012, 34, 601-610.
140. Pallebage-Gamarallage, M.; Lam, V.; Takechi, R.; Galloway, S.; Clark, K.; Mamo, J. Restoration of dietary-fat induced blood-brain barrier dysfunction by anti-inflammatory lipid-modulating agents. Lipids Health Dis, 2012, 11, 117.
141. Sato, N.; Shinohara, M.; Rakugi, H.; Morishita, R. Dual effects of statins on Aβ metabolism: upregulation of the degradation of APPCTF and Aβ clearance. Neuro-Degenerative Diseases, 2012, 10, 305-308.
142. Hamano, T.; Yen, S. H.; Gendron, T.; Ko, L. W.; Kuriyama, M. Pitavastatin decreases tau levels via the inactivation of Rho/ROCK. Neurobiology of Aging, 2012, 33, 2306-2320.
143. Kurata, T.; Kawai, H.; Miyazaki, K.; Kozuki, M.; Morimoto, N.; Ohta, Y.; Ikeda, Y.; Abe, K. Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain. Journal of the Neurological Sciences, 2012, 322, 59-63.
144. Tong, X. K.; Lecrux, C.; Rosa-Neto, P.; Hamel, E. Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. The Journal of Neuroscience, 2012, 32, 4705-4715.
145. Jiang, X.; Guo, M.; Su, J.; Lu, B.; Ma, D.; Zhang, R.; Yang, L.; Wang, Q.; Ma, Y.; Fan, Y. Simvastatin blocks blood-brain barrier disruptions induced by elevated cholesterol both in vivo and in vitro. Int. J. Alzheimers Dis, 2012, 2012, 109324.
146. McGuinness, B.; O'Hare, J.; Craig, D.; Bullock, R.; Malouf, R.; Passmore, P. Cochrane review on "Statins for the treatment of dementia. " Int. J. Geriatr. Psychiatry, 2013, 28(2), 119-126.
147. Padala, K. P.; Padala, P. R.; McNeilly, D. P.; Geske, J. A.; Sullivan, D. H.; Potter, J. F. The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study. Am. J. Geriatr. Pharmacother, 2012, 10, 296-302.
148. Santos, D. B.; Peres, K. C.; Ribeiro, R. P.; Colle, D.; Santos, dos, A. A.; Moreira, E. L. G.; Souza, D. O. G.; Figueiredo, C. P.; Farina, M. Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid peptide in mice. Experimental Neurology, 2012, 233, 767-775.
149. Watson, G. S.; Cholerton, B. A.; Reger, M. A.; Baker, L. D.; Plymate, S. R.; Asthana, S.; Fishel, M. A.; Kulstad, J. J.; Green, P. S.; Cook, D. G.; Kahn, S. E.; Keeling, M. L.; Craft, S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. The American Journal of Geriatric Psychiatry, 2005, 13, 950-958.
150. Toledo, E. M.; Inestrosa, N. C. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Molecular Psychiatry, 2010, 15, 272-285.
151. Pedersen, W. A.; McMillan, P. J.; Kulstad, J. J.; Leverenz, J. B.; Craft, S.; Haynatzki, G. R. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Experimental Neurology, 2006, 199, 265-273.
152. Escribano, L.; Simón, A. M.; Gimeno, E.; Cuadrado-Tejedor, M.; López de Maturana, R.; García-Osta, A.; Ricobaraza, A.; Pérez-Mediavilla, A.; Del Río, J.; Frechilla, D. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology, 2010, 35, 1593-1604.
153. De Felice, F. G.; Vieira, M. N. N.; Bomfim, T. R.; Decker, H.; Velasco, P. T.; Lambert, M. P.; Viola, K. L.; Zhao, W. Q.; Ferreira, S. T.; Klein, W. L. Protection of synapses against Alzheimer'slinked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proceedings of the National Academy of Sciences, 2009, 106, 1971-1976.
154. Cowley, T. R.; O'Sullivan, J.; Blau, C.; Deighan, B. F.; Jones, R.; Kerskens, C.; Richardson, J. C.; Virley, D.; Upton, N.; Lynch, M. A. Rosiglitazone attenuates the age-related changes in astrocytosis and the deficit in LTP. Neurobiology of Aging, 2012, 33, 162-175.
155. Denner, L. A.; Rodriguez-Rivera, J.; Haidacher, S. J.; Jahrling, J. B.; Carmical, J. R.; Hernandez, C. M.; Zhao, Y.; Sadygov, R. G.; Starkey, J. M.; Spratt, H.; Luxon, B. A.; Wood, T. G.; Dineley, K. T. Cognitive enhancement with rosiglitazone links the hippocampal PPAR and ERK MAPK signaling pathways. The Journal of Neuroscience, 2012, 32, 16725-16735.
156. Martin, H. L.; Mounsey, R. B.; Mustafa, S.; Sathe, K.; Teismann, P. Pharmacological manipulation of peroxisome proliferatoractivated receptor (PPAR+) reveals a role for anti-oxidant protection in a model of Parkinson's disease. Experimental Neurology, 2012, 235, 528-538.
157. Tzimopoulou, S.; Cunningham, V. J.; Nichols, T. E.; Searle, G.; Bird, N. P.; Mistry, P.; Dixon, I. J.; Hallett, W. A.; Whitcher, B.; Brown, A. P.; Zvartau-Hind, M.; Lotay, N.; Lai, R. Y. K.; Castiglia, M.; Jeter, B.; Matthews, J. C.; Chen, K.; Bandy, D.; Reiman, E. M.; Gold, M.; Rabiner, E. A.; Matthews, P. M. A multi-center randomized proof-of-concept clinical trial applying [íF]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. Journal of Alzheimer's Disease, 2010, 22, 1241-1256.
158. Gold, M.; Alderton, C.; Zvartau-Hind, M.; Egginton, S.; Saunders, A. M.; Irizarry, M.; Craft, S.; Landreth, G.; Linnamägi, U.; Sawchak, S. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebocontrolled phase III study. Dement. Geriatr. Cogn. Disord, 2010, 30, 131-146.
159. Harrington, C.; Sawchak, S.; Chiang, C.; Davies, J.; Donovan, C.; Saunders, A. M.; Irizarry, M.; Jeter, B.; Zvartau-Hind, M.; van Dyck, C. H.; Gold, M. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Current Alzheimer Research, 2011, 8, 592-606.
160. Risner, M. E.; Saunders, A. M.; Altman, J. F. B.; Ormandy, G. C.; Craft, S.; Foley, I. M.; Zvartau-Hind, M. E.; Hosford, D. A.; Roses, A. D.; Rosiglitazone in Alzheimer's Disease Study Group. Efficacy of rosiglitazone in a genetically defined population with mild-tomoderate Alzheimer's disease. Pharmacogenomics J, 2006, 6, 246-254.
161. Miller, B. W.; Willett, K. C.; Desilets, A. R. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. Ann. Pharmacother, 2011, 45, 1416-1424.
162. Moon, J. H.; Kim, H. J.; Yang, A. H.; Kim, H. M.; Lee, B. W.; Kang, E. S.; Lee, H. C.; Cha, B. S. The effect of rosiglitazone on LRP1 expression and amyloid uptake in human brain microvascular endothelial cells: a possible role of a low-dose thiazolidinedione for dementia treatment. Int. J. Neuropsychopharmacol, 2011, 1-8.
163. Nicolakakis, N.; Aboulkassim, T.; Ongali, B.; Lecrux, C.; Fernandes, P.; Rosa-Neto, P.; Tong, X. K.; Hamel, E. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferatoractivated receptor gamma agonist. The Journal of Neuroscience, 2008, 28, 9287-9296.
164. Heneka, M. T.; Sastre, M.; Dumitrescu-Ozimek, L.; Hanke, A.; Dewachter, I;, Kuiperi, C.; O'Banion, K.; Klockgether, T.; Van Leuven, F.; Landreth, G. E. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain, 2005, 128, 1442-1453.
165. Mandrekar-Colucci, S.; Karlo, J. C.; Landreth, G. E. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-β-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. The Journal of Neuroscience, 2012, 32, 10117-10128.
166. Xiang, G. Q.; Tang, S. S.; Jiang, L. Y.; Hong, H.; Li, Q.; Wang, C.; Wang, X. Y.; Zhang, T. T.; Yin, L. PPAR agonist pioglitazone improves scopolamine-induced memory impairment in mice. J. Pharm. Pharmacol, 2012, 64, 589-596.
167. Yin, Q. Q.; Pei, J. J.; Xu, S.; Luo, D. Z.; Dong, S. Q.; Sun, M. H.; You, L.; Sun, Z. J.; Liu, X. P. Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance rats. PloS One, 2013, 8, e59313.
168. Searcy, J. L.; Phelps, J. T.; Pancani, T.; Kadish, I.; Popovic, J.; Anderson, K. L.; Beckett, T. L.; Murphy, M. P.; Chen, K. C.; Blalock, E. M.; Landfield, P. W.; Porter, N. M.; Thibault, O. Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. Journal of Alzheimer's Disease, 2012, 30, 943-961.
169. Sato, T.; Hanyu, H.; Hirao, K.; Kanetaka, H.; Sakurai, H.; Iwamoto, T. Efficacy of PPAR-α agonist pioglitazone in mild Alzheimer disease. Neurobiology of Aging, 2011, 32, 1626-1633.
170. Hanyu, H.; Sato, T.; Kiuchi, A.; Sakurai, H.; Iwamoto, T. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. Journal of the American Geriatrics Society, 2009, 57, 177-179.
171. Hanyu, H.; Sato, T.; Sakurai, H.; Iwamoto, T. The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer's disease. Journal of the American Geriatrics Society, 2010, 58, 1000-1001.
172. Geldmacher, D. S.; Fritsch, T.; McClendon, M. J.; Landreth, G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch. Neurol, 2011, 68, 45-50.
173. Chen, Y.; Zhou, K.; Wang, R.; Liu, Y.; Kwak, Y. D.; Ma, T.; Thompson, R. C.; Zhao, Y.; Smith, L.; Gasparini, L.; Luo, Z.; Xu, H.; Liao, F. F. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via upregulating BACE1 transcription. Proceedings of the National Academy of Sciences, 2009, 106, 3907-3912.
174. Kickstein, E.; Krauss, S.; Thornhill, P.; Rutschow, D.; Zeller, R.; Sharkey, J.; Williamson, R.; Fuchs, M.; Köhler, A.; Glossmann, H.; Schneider, R.; Sutherland, C.; Schweiger, S. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proceedings of the National Academy of Sciences, 2010, 107, 21830-21835.
175. Gupta, A.; Bisht, B.; Dey, C. S. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer'slike changes. Neuropharmacology, 2011, 60, 910-920.
176. Li, J.; Deng, J.; Sheng, W.; Zuo, Z. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacology Biochemistry and Behavior, 2012, 101, 564-574.
177. McClean, P. L.; Gault, V. A.; Harriott, P.; Hölscher, C. Glucagonlike peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease. Eur. J. Pharmacol, 2010, 630, 158-162.
178. McClean, P. L.; Parthsarathy, V.; Faivre, E.; Holscher, C. The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease. The Journal of Neuroscience, 2011, 31, 6587-6594.
179. Long-Smith, C. M.; Manning, S.; McClean, P. L.; Coakley, M. F.; O'Halloran, D. J.; Hölscher, C.; O'Neill, C. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-α plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromolecular Medicine, 2013, 15, 102-114.
180. Parthsarathy, V.; Hölscher, C. The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur. J. Pharmacol, 2013, 700, 42-50.
181. Parthsarathy, V.; Hölscher, C. Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PloS One, 2013, 8, e58784.
182. Egefjord, L.; Gejl, M.; Møller, A.; Brændgaard, H.; Gottrup, H.; Antropova, O.; Møller, N.; Poulsen, H. E.; Gjedde, A.; Brock, B.; Rungby, J. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer's disease-protocol for a controlled, randomized double-blinded trial. Dan. Med. J, 2012, 59, A4519.
183. Perry, T.; Lahiri, D. K.; Sambamurti, K.; Chen, D.; Mattson, M. P.; Egan, J. M.; Greig, N. H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. Journal of Neuroscience Research, 2003, 72, 603-612.
184. Chen, S.; Liu, A. R.; An, F. M.; Yao, W. B.; Gao, X. D. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age, 2011, 34(5), 1211-1224.
185. Li, Y.; Chigurupati, S.; Holloway, H. W.; Mughal, M.; Tweedie, D.; Bruestle, D. A.; Mattson, M. P.; Wang, Y.; Harvey, B. K.; Ray, B.; Lahiri, D. K.; Greig, N. H. Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PloS One, 2012, 7, e32008.
186. Bomfim, T. R.; Forny-Germano, L.; Sathler, L. B.; Brito-Moreira, J.; Houzel, J. C.; Decker, H.; Silverman, M. A.; Kazi, H.; Melo, H. M.; McClean, P. L.; Hölscher, C.; Arnold, S. E.; Talbot, K.; Klein, W. L.; Munoz, D. P.; Ferreira, S. T.; De Felice, F. G. An antidiabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers. J. Clin. Invest, 2012, 122, 1339-1353.
187. Huang, H. J.; Chen, Y. H.; Liang, K. C.; Jheng, Y. S.; Jhao, J. J.; Su, M. T.; Lee-Chen, G. J.; Hsieh-Li, H. M. Exendin-4 protected against cognitive dysfunction in hyperglycemic mice receiving an intrahippocampal lipopolysaccharide injection. PloS One, 2012, 7, e39656.
188. Tweedie, D.; Rachmany, L.; Rubovitch, V.; Lehrmann, E.; Zhang, Y.; Becker, K. G.; Perez, E.; Miller, J.; Hoffer, B. J.; Greig, N. H.; Pick, C. G. Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Experimental Neurology, 2013, 239, 170-182.
189. Kim, D. H.; Huh, J. W.; Jang, M.; Suh, J. H.; Kim, T. W.; Park, J. S.; Yoon, S. Y. Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures. Neurobiology of Disease, 2012, 46, 52-58.
190. Tamaki, C.; Ohtsuki, S.; Terasaki, T. Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1-40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol. Pharmacol, 2007, 72, 850-855.
191. Reger, M. A.; Watson, G. S.; Green, P. S.; Baker, L. D.; Cholerton, B.; Fishel, M. A.; Plymate, S. R.; Cherrier, M. M.; Schellenberg, G. D.; Frey, W. H.; Craft, S. Intranasal insulin administration dosedependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. Journal of Alzheimer's Disease, 2008, 13, 323-331.
192. Jiang, L. H.,; Zhang, Y. N.; Wu, X. W.; Song, F. F.; Guo, D. Y. Effect of insulin on the cognizing function and expression of hippocampal Abeta1-40 of rat with Alzheimer disease. Chin. Med. J, 2008, 121, 827-831.
193. Yang, Y.; Ma, D.; Wang, Y.; Jiang, T.; Hu, S.; Zhang, M.; Yu, X.; Gong, C. X. Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes. Journal of Alzheimer's Disease, 2013, 33, 329-338.
194. Craft, S.; Asthana, S.; Newcomer, J. W.; Wilkinson, C. W.; Matos, I. T.; Baker, L. D.; Cherrier, M.; Lofgreen, C.; Latendresse, S.; Petrova, A.; Plymate, S.; Raskind, M.; Grimwood, K.; Veith, R. C. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch. Gen. Psychiatry, 1999, 56, 1135-1140.
195. Reger, M. A.; Watson, G. S.; Frey, W. H.; Baker, L. D.; Cholerton, B.; Keeling, M. L.; Belongia, D. A.; Fishel, M. A.; Plymate, S. R.; Schellenberg, G. D.; Cherrier, M. M.; Craft, S. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiology of Aging, 2006, 27, 451-458.
196. Reger, M. A.; Watson, G. S.; Green, P. S.; Wilkinson, C. W.; Baker, L. D.; Cholerton, B.; Fishel, M. A.; Plymate, S. R.; Breitner, J. C. S.; DeGroodt, W.; Mehta, P.; Craft, S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology, 2008, 70, 440-448.
197. Plastino, M.; Fava, A.; Pirritano, D.; Cotronei, P.; Sacco, N.; Sperlì, T.; Spanò, A.; Gallo, D.; Mungari, P.; Consoli, D.; Bosco, D. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. Journal of the Neurological Sciences, 2010, 288, 112-116.
198. Claxton, A.; Baker, L. D.; Wilkinson, C. W.; Trittschuh, E. H.; Chapman, D.; Watson, G. S.; Cholerton, B.; Plymate, S. R.; Arbuckle, M.; Craft, S. Sex and ApoE Genotype Differences in Treatment Response to Two Doses of Intranasal Insulin in Adults with Mild Cognitive Impairment or Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 789-797.
199. Karczewska-Kupczewska, M.; Lelental, N.; Adamska, A.; Nikoajuk, A.; Kowalska, I.; Górska, M.; Zimmermann, R.; Kornhuber, J.; Strczkowski, M.; Lewczuk, P. The influence of insulin infusion on the metabolism of amyloid peptides in plasma. Alzheimers Dement, 2013, 9(4), 400-405.
200. Craft, S.; Baker, L. D.; Montine, T. J.; Minoshima, S.; Watson, G. S.; Claxton, A.; Arbuckle, M.; Callaghan, M.; Tsai, E.; Plymate, S. R.; Green, P. S.; Leverenz, J.; Cross, D.; Gerton, B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol, 2012, 69, 29-38.
201. Hermann, D.; Mezler, M.; Müller, M. K.; Wicke, K.; Gross, G.; Draguhn, A.; Bruehl, C.; Nimmrich, V. Synthetic A oligomers (A 1-42 globulomer) modulate presynaptic calcium currents: Prevention of A-induced synaptic deficits by calcium channel blockers. Eur. J. Pharmacol, 2013, 702, 44-55.
202. Paris, D.; Quadros, A.; Humphrey, J.; Patel, N.; Crescentini, R.; Crawford, F.; Mullan, M. Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Research, 2004, 999, 53-61.
203. Paris, D.; Bachmeier, C.; Patel, N.; Quadros, A.; Volmar, C. H.; Laporte, V.; Ganey, J.; Beaulieu-Abdelahad, D.; Ait-Ghezala, G.; Crawford, F.; Mullan, M. J. Selective antihypertensive dihydropyridines lower A accumulation by targeting both the production and the clearance of A across the blood-brain barrier. Mol. Med, 2011, 17, 149-162.
204. Bachmeier, C.; Beaulieu-Abdelahad, D.; Mullan, M.; Paris, D. Selective dihydropyiridine compounds facilitate the clearance of-amyloid across the blood-brain barrier. Eur. J. Pharmacol, 2011, 659, 124-129.
205. Anekonda, T. S.; Quinn, J. F.; Harris, C.; Frahler, K.; Wadsworth, T. L.; Woltjer, R. L. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiology of Disease, 2011, 41, 62-70.
206. Hashioka, S.; Klegeris, A.; McGeer, P. L. Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers. Neuropharmacology, 2012, 63, 685-691.
207. Kennelly, S. P.; Abdullah, L.; Paris, D.; Parish, J.; Mathura, V.; Mullan, M.; Crawford, F.; Lawlor, B. A.; Kenny, R. A. Demonstration of safety in Alzheimer's patients for intervention with an antihypertensive drug Nilvadipine: results from a 6-week open label study. Int. J. Geriatr. Psychiatry, 2011, 26, 1038-1045.
208. Hanyu, H.; Hirao, K.; Shimizu, S.; Sato, T.; Kiuchi, A.; Iwamoto, T. Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. Int. J. Geriatr. Psychiatry, 2007, 22, 1264-1266.
209. López-Arrieta, J. M.; Birks, J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst. Rev, 2002, CD000147.
210. Popovi, M.; Caballero-Bleda, M.; Popovi, N.; Bokonji, D.; Dobri, S. Neuroprotective effect of chronic verapamil treatment on cognitive and noncognitive deficits in an experimental Alzheimer's disease in rats. Int. J. Neurosci, 1997, 92, 79-93.
211. Davies, N. M.; Kehoe, P. G.; Ben-Shlomo, Y.; Martin, R. M. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. Journal of Alzheimer's Disease, 2011, 26, 699-708.
212. Forette, F.; Seux, M. L.; Staessen, J. A.; Thijs, L.; Birkenhäger, W. H.; Babarskiene, M. R.; Babeanu, S.; Bossini, A.; Gil-Extremera, B.; Girerd, X.; Laks, T.; Lilov, E.; Moisseyev, V.; Tuomilehto, J.; Vanhanen, H.; Webster, J.; Yodfat, Y.; Fagard, R. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet, 1998, 352, 1347-1351.
213. Qiu, W. W. Q.; Lai, A.; Mon, T.; Mwamburi, M.; Taylor, W.; Rosenzweig, J.; Kowall, N.; Stern, R.; Zhu, H.; Steffens, D. C. (2013) Angiotensin Converting Enzyme Inhibitors and Alzheimer Disease in the Presence of the Apolipoprotein E4 Allele. The American Journal of Geriatric Psychiatry, 2013, [In Press].
214. Ferrington, L.; Miners, J. S.; Palmer, L. E.; Bond, S. M.; Povey, J. E.; Kelly, P. A. T.; Love, S.; Horsburgh, K. J.; Kehoe, P. G. Angiotensin II-inhibiting drugs have no effect on intraneuronal A or oligomeric A levels in a triple transgenic mouse model of Alzheimer's disease. Am. J. Transl. Res, 2011, 3, 197.
215. Ferrington, L.; Palmer, L. E.; Love, S.; Horsburgh, K. J.; Kelly, P. A.; Kehoe, P. G. Angiotensin II-inhibition: effect on Alzheimer's pathology in the aged triple transgenic mouse. Am. J. Transl. Res, 2012, 4, 151-164.
216. Wharton, W.; Stein, J. H.; Korcarz, C.; Sachs, J.; Olson, S. R.; Zetterberg, H.; Dowling, M.; Ye, S.; Gleason, C. E.; Underbakke, G.; Jacobson, L. E.; Johnson, S. C.; Sager, M. A.; Asthana, S.; Carlsson, C. M. The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. Journal of Alzheimer's Disease, 2012, 32, 147-156.
217. Hajjar, I.; Brown, L.; Mack, W. J.; Chui, H. Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch. Neurol, 2012, 69, 1632-1638.
218. Wang, J.; Ho, L.; Chen, L.; Zhao, Z.; Zhao, W.; Qian, X.; Humala, N.; Seror, I.; Bartholomew, S.; Rosendorff, C.; Pasinetti, G. M. Valsartan lowers brain-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J. Clin. Invest, 2007, 117, 3393-3402.
219. Takeda, S.; Sato, N.; Takeuchi, D.; Kurinami, H.; Shinohara, M.; Niisato, K.; Kano, M.; Ogihara, T.; Rakugi, H.; Morishita, R. Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension, 2009, 54, 1345-1352.
220. Shindo, T.; Takasaki, K.; Uchida, K.; Onimura, R.; Kubota, K.; Uchida, N.; Irie, K.; Katsurabayashi, S.; Mishima, K.; Nishimura, R.; Fujiwara, M.; Iwasaki, K. Ameliorative effects of telmisartan on the inflammatory response and impaired spatial memory in a rat model of Alzheimer's disease incorporating additional cerebrovascular disease factors. Biol. Pharm. Bull, 2012, 35, 2141-2147.
221. Furiya, Y.; Ryo, M.; Kawahara, M.; Kiriyama, T.; Morikawa, M.; Ueno, S. Renin-angiotensin system blockers affect cognitive decline and serum adipocytokines in Alzheimer's disease. Alzheimers Dement, 2012, [In Press].
222. Kume, K.; Hanyu, H.; Sakurai, H.; Takada, Y.; Onuma, T.; Iwamoto, T. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. Geriatr. Gerontol. Int, 2012, 12, 207-214.
223. Wagner, G.; Icks, A.; Abholz, H. H.; Schröder-Bernhardi, D.; Rathmann, W.; Kostev, K. Antihypertensive treatment and risk of dementia: a retrospective database study. Int. J. Clin. Pharmacol. Ther, 2012, 50, 195-201.
224. Dobarro, M.; Orejana, L.; Aguirre, N.; Ramírez, M. J. Propranolol reduces cognitive deficits, amyloid-levels, tau phosphorylation and insulin resistance in response to chronic corticosterone administration. Int. J. Neuropsychopharmacol, 2013, 16(6), 1351-1360.
225. Dobarro, M.; Orejana, L.; Aguirre, N.; Ramírez, M. J. Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model. Neuropharmacology, 2013, 64, 137-144.
226. Saharia, K.; Arya, U.; Kumar, R.; Sahu, R.; Das, C. K.; Gupta, K.; Dwivedi, H.; Subramaniam, J. R. Reserpine modulates neurotransmitter release to extend lifespan and alleviate age-dependent Aβ proteotoxicity in Caenorhabditis elegans. Exp. Gerontol, 2012, 47, 188-197.
227. Chu, J.; Praticò, D. Pharmacologic Blockade of 5-Lipoxygenase Improves the Amyloidotic Phenotype of an Alzheimer's Disease Transgenic Mouse Model. AJPA, 2011, 178, 1762-1769.
228. Kumar, A.; Prakash, A.; Pahwa, D.; Mishra, J. Montelukast potentiates the protective effect of rofecoxib against kainic acid-induced cognitive dysfunction in rats. Pharmacology Biochemistry and Behavior, 2012, 103, 43-52.
229. Atamna, H.; Nguyen, A.; Schultz, C.; Boyle, K.; Newberry, J.; Kato, H.; Ames, B. N. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. The FASEB Journal, 2008, 22, 703-712.
230. Wischik, C. M.; Edwards, P. C.; Lai, R. Y.; Roth, M.; Harrington, C. R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 11213-11218.
231. Congdon, E. E.; Wu, J. W.; Myeku, N.; Figueroa, Y. H.; Herman, M.; Marinec, P. S.; Gestwicki, J. E.; Dickey, C. A.; Yu, W. H.; Duff, K. E. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy, 2012, 8, 609-622.
232. Riha, P. D.; Rojas, J. C.; Gonzalez-Lima, F. Beneficial network effects of methylene blue in an amnestic model. Neuroimage, 2011, 54, 2623-2634.
233. O'Leary, J. C.; Li, Q.; Marinec, P.; Blair, L. J.; Congdon, E. E.; Johnson, A. G.; Jinwal, U. K.; Koren, J.; Jones, J. R.; Kraft, C.; Peters, M.; Abisambra, J. F.; Duff, K. E.; Weeber, E. J.; Gestwicki, J. E.; Dickey, C. A. Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Molecular Neurodegeneration, 2010, 5, 45.
234. Necula, M.; Breydo, L.; Milton, S.; Kayed, R.; van der Veer, W. E.; Tone, P.; Glabe, C. G. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry, 2007, 46, 8850-8860.
235. Medina, D. X.; Caccamo, A.; Oddo, S. Methylene blue reduces á levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathology, 2011, 21, 140-149.
236. Jinwal, U. K.; Miyata, Y.; Koren, J.; Jones, J. R.; Trotter, J. H.; Chang, L.; O'Leary, J.; Morgan, D.; Lee, D. C.; Shults, C. L.; Rousaki, A.; Weeber, E. J.; Zuiderweg, E. R. P.; Gestwicki, J. E.; Dickey, C. A. Chemical Manipulation of Hsp70 ATPase Activity Regulates Tau Stability. The Journal of Neuroscience, 2009, 29, 12079-12088.
237. Irwin, J. A.; Wong, H. E.; Kwon, I. Different fates of Alzheimer's disease amyloid-α fibrils remodeled by biocompatible small molecules. Biomacromolecules, 2013, 14, 264-274.
238. Poteet, E.; Winters, A.; Yan, L. J.; Shufelt, K.; Green, K. N.; Simpkins, J. W.; Wen, Y.; Yang, S. H. Neuroprotective actions of methylene blue and its derivatives. PloS One, 2012, 7, e48279.
239. Xie, L.; Li, W.; Winters, A.; Yuan, F.; Jin, K.; Yang, S. Methylene blue induces macroautophagy through 5' adenosine monophosphate-activated protein kinase pathway to protect neurons from serum deprivation. Front Cell Neurosci, 2013, 7, 56.
240. van Bebber, F.; Paquet, D.; Hruscha, A.; Schmid, B.; Haass, C. Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish. Neurobiology of Disease, 2010, 39, 265-271.
241. Gura, T. Hope in Alzheimer's fight emerges from unexpected places. Nat Med, 2008, 14, 894-894.
242. Newhouse, P.; Kellar, K.; Aisen, P.; White, H.; Wesnes, K.; Coderre, E.; Pfaff, A.; Wilkins, H.; Howard, D.; Levin, E. D. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology, 2012, 78, 91-101.
243. Mousavi, M.; Hellström-Lindahl, E. Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro. Neurochem. Int, 2009, 54, 237-244.
244. Srivareerat, M.; Tran, T. T.; Salim, S.; Aleisa, A. M.; Alkadhi, K. A. Chronic nicotine restores normal Aβ levels and prevents shortterm memory and E-LTP impairment in Aβ rat model of Alzheimer's disease. Neurobiology of Aging, 2011, 32, 834-844.
245. Alkadhi, K. A.; Alzoubi, K. H.; Srivareerat, M.; Tran, T. T. Elevation of BACE in an Aβ rat model of Alzheimer's disease: exacerbation by chronic stress and prevention by nicotine. Int. J. Neuropsychopharmacol, 2012, 15, 223-233.
246. Sabbagh, M. N.; Walker, D. G.; Reid, R. T.; Stadnick, T.; Anand, K.; Lue, L. F. Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (Sw, Ind). Neuroscience Letters, 2008, 448, 217-220.
247. Deng, J.; Shen, C.; Wang, Y. J.; Zhang, M.; Li, J.; Xu, Z. Q.; Gao, C. Y.; Fang, C. Q.; Zhou, H. D. Nicotine exacerbates tau phosphorylation and cognitive impairment induced by amyloid-beta 25-35 in rats. Eur. J. Pharmacol, 2010, 637, 83-88.
248. Naddafi, F.; Reza Haidari, M.; Azizi, G.; Sedaghat, R.; Mirshafiey, A. Novel Therapeutic Approach by Nicotine in Experimental Model of Multiple Sclerosis. Innov. Clin. Neurosci, 2013, 10, 20-25.
249. Chakroborty, S.; Briggs, C.; Miller, M. B.; Goussakov, I.; Schneider, C.; Kim, J.; Wicks, J.; Richardson, J. C.; Conklin, V.; Cameransi, B. G.; Stutzmann, G. E. Stabilizing ER Ca2+ channel function as an early preventative strategy for Alzheimer's disease. PloS One, 2012, 7, e52056.
250. Costa, R. O.; Ferreiro, E.; Oliveira, C. R.; Pereira, C. M. F. Inhibition of mitochondrial cytochrome c oxidase potentiates Aβ-induced ER stress and cell death in cortical neurons. Molecular and Cellular Neurosciences, 2013, 52, 1-8.
251. Oulès, B.; Del Prete, D.; Greco, B.; Zhang, X.; Lauritzen, I.; Sevalle, J.; Moreno, S.; Paterlini-Bréchot, P.; Trebak, M.; Checler, F.; Benfenati, F.; Chami, M. Ryanodine receptor blockade reduces amyloid-α load and memory impairments in Tg2576 mouse model of Alzheimer disease. The Journal of Neuroscience, 2012, 32, 11820-11834.
252. Peng, J.; Liang, G.; Inan, S.; Wu, Z.; Joseph, D. J.; Meng, Q.; Peng, Y.; Eckenhoff, M. F.; Wei, H. Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice. Neuroscience Letters, 2012, 516, 274-279.
253. Kong, M.; Ba, M. Protective effects of diazoxide against Aíβ-induced PC12 cell apoptosis due to prevention of endoplasmic reticulum stress. Neuroreport, 2012, 23, 493-497.
254. Takasugi, N.; Sasaki, T.; Ebinuma, I.; Osawa, S.; Isshiki, H.; Takeo, K.; Tomita, T.; Iwatsubo, T. FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-α Production in Neurons. PloS One, 2013, 8, e64050.
255. Karapetyan, Y. E.; Sferrazza, G. F.; Zhou, M.; Ottenberg, G.; Spicer, T.; Chase, P.; Fallahi, M.; Hodder, P.; Weissmann, C.; Lasmézas, C. I. Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents. Proceedings of the National Academy of Sciences, 2013, 110, 7044-7049.
256. Ashburn, T. T.; Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug. Discov, 2004, 3, 673-683.
257. Boguski, M. S.; Mandl, K. D.; Sukhatme, V. P. Drug discovery. Repurposing with a difference. Science, 2009, 324, 1394-1395.
258. Schneider, P.; Tanrikulu, Y.; Schneider, G. Self-organizing maps in drug discovery: compound library design, scaffold-hopping, repurposing. Curr. Med. Chem, 2009, 16, 258-266.
259. Iorio, F.; Bosotti, R.; Scacheri, E.; Belcastro, V.; Mithbaokar, P.; Ferriero, R.; Murino, L.; Tagliaferri, R.; Brunetti-Pierri, N.; Isacchi, A.; di Bernardo, D. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proceedings of the National Academy of Sciences, 2010, 107, 14621-14626.
260. Loging, W.; Rodriguez-Esteban, R.; Hill, J.; Freeman, T.; Miglietta, J. Cheminformatic/bioinformatic analysis of large corporate databases: Application to drug repurposing. Drug Discov. Today, 2011, 8, 109-116.
261. Deftereos, S. N.; Andronis, C.; Friedla, E. J.; Persidis, A.; Persidis, A. Drug repurposing and adverse event prediction using highthroughput literature analysis. Rev Syst Biol Med, 2011, 3, 323-334.
262. Oprea, T. I.; Bauman, J. E.; Bologa, C. G.; Buranda, T.; Chigaev, A.; Edwards, B. S.; Jarvik, J. W.; Gresham, H. D.; Haynes, M. K.; Hjelle, B.; Hromas, R.; Hudson, L.; Mackenzie, D. A.; Muller, C. Y.; Reed, J. C.; Simons, P. C.; Smagley, Y.; Strouse, J.; Surviladze, Z.; Thompson, T.; Ursu, O.; Waller, A.; Wandinger-Ness, A.; Winter, S. S.; Wu, Y.; Young, S. M.; Larson, R. S.; Willman, C.; Sklar, L. A. Drug Repurposing from an Academic Perspective. Drug Discovery Today. Therapeutic strategies, 2011, 8, 61-69.
263. Reaume, A. G. Drug repurposing through nonhypothesis driven phenotypic screening Drug Discovery Today. Therapeutic Strategies, 2012, 8(3), 85-88.
264. Corbett, A.; Pickett, J.; Burns, A.; Corcoran, J.; Dunnett, S. B.; Edison, P.; Hagan, J. J.; Holmes, C.; Jones, E.; Katona, C.; Kearns, I.; Kehoe, P.; Mudher, A.; Passmore, A.; Shepherd, N.; Walsh, F.; Ballard, C. Drug repositioning for Alzheimer's disease. Nat. Rev. Drug Discov, 2012, 11, 833-846.
265. Lauterbach, E. C.; Mendez, M. F. Psychopharmacological neuroprotection in neurodegenerative diseases, part III: criteria-based assessment: a report of the ANPA committee on research. J. Neuropsychiatry Clin. Neurosci, 2011, 23, 242-260.